CN101791302B - 含阿魏酸钠的药物组合物及其制备方法 - Google Patents
含阿魏酸钠的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN101791302B CN101791302B CN2010101130199A CN201010113019A CN101791302B CN 101791302 B CN101791302 B CN 101791302B CN 2010101130199 A CN2010101130199 A CN 2010101130199A CN 201010113019 A CN201010113019 A CN 201010113019A CN 101791302 B CN101791302 B CN 101791302B
- Authority
- CN
- China
- Prior art keywords
- sodium ferulate
- injection
- mannitol
- adds
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000008215 water for injection Substances 0.000 claims abstract description 25
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 24
- 229930195725 Mannitol Natural products 0.000 claims abstract description 24
- 239000000594 mannitol Substances 0.000 claims abstract description 24
- 235000010355 mannitol Nutrition 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000010792 warming Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000003610 charcoal Substances 0.000 claims description 4
- 238000005056 compaction Methods 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 abstract description 20
- 238000002347 injection Methods 0.000 abstract description 20
- 239000000126 substance Substances 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940001482 sodium sulfite Drugs 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical compound OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000009686 powder production technique Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Abstract
Description
组成 | 用量(g)1 2 3 4 5 6 7 8 9 10 11 |
阿魏酸钠 | 10 10 10 10 10 10 10 10 10 10 10 |
甘露醇 | 30 30 30 30 30 30 30 30 30 30 30 |
亚硫酸氢钠 | 0.002 |
亚硫酸钠 | 0.002 |
甲硫氨酸 | 0.002 |
焦亚硫酸氢钠 | 0.002 |
甘氨酸 | 0.002 |
L-半胱氨酸 | 0.002 |
N-乙酰本胱氨酸 | 0.002 |
柠檬酸 | 0.002 |
乙二胺四乙酸 | 0.002 |
依地酸钙钠 | 0.002 |
0天含量(%) | 100.1 99.8 99.9 99.9 100.3 99.6 99.9 99.7 99.8 99.8 100.2 |
光照10天含量(%) | 82.1 83.0 83.1 83.3 84.2 86.3 84.5 84.6 83.9 87.2 92.5 |
高温10天含量(%) | 85.5 86.1 86.5 86.3 85.9 88.7 86.2 86.0 85.9 88.2 93.5 |
0天有关物质(%) | 0.87 0.89 0.91 0.90 0.91 0.93 0.89 0.94 0.85 0.88 0.89 |
光照10天有关物质比(%) | 6.62 6.49 6.28 6.55 6.48 5.59 6.04 6.17 6.09 5.38 2.95 |
高温10天有关物质(%) | 4.96 4.89 4.91 4.75 4.62 4.19 4.68 4.72 4.80 4.06 2.84 |
0月 6月 12月 18月 24月 |
本发明实施例1 0.91 0.90 0.99 1.12 1.28 |
本发明实施例2 0.85 0.88 1.01 1.17 1.32 |
本发明实施例3 0.89 0.86 0.98 1.20 1.40 |
本发明实施例4 0.92 0.93 0.99 1.06 1.29 |
本发明实施例5 0.85 0.92 1.09 1.22 1.45 |
对比实施例1 0.90 1.26 2.53 3.65 4.56 |
对比实施例2 0.90 1.13 2.05 2.94 3.71 |
对比实施例3 0.92 1.18 1.99 2.80 3.58 |
0月 6月 12月 18月 24月 |
本发明实施例1 99.9 99.8 99.5 99.2 98.6 |
本发明实施例2 99.7 99.7 99.3 98.9 98.6 |
本发明实施例3 100.2 100.0 99.8 99.6 99.0 |
本发明实施例4 100.5 100.3 100.1 99.5 99.4 |
本发明实施例5 99.9 99.6 99.2 98.8 98.0 |
对比实施例1 100.2 98.4 96.5 94.0 91.9 |
对比实施例2 99.8 98.7 98.0 96.4 93.6 |
对比实施例3 99.8 99.7 97.7 95.8 94.2 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101130199A CN101791302B (zh) | 2010-02-24 | 2010-02-24 | 含阿魏酸钠的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101130199A CN101791302B (zh) | 2010-02-24 | 2010-02-24 | 含阿魏酸钠的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101791302A CN101791302A (zh) | 2010-08-04 |
CN101791302B true CN101791302B (zh) | 2011-09-21 |
Family
ID=42584363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101130199A Expired - Fee Related CN101791302B (zh) | 2010-02-24 | 2010-02-24 | 含阿魏酸钠的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101791302B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102085366B (zh) | 2011-01-26 | 2012-12-26 | 中国医学科学院医学生物学研究所 | 一种复合疫苗佐剂 |
CN102657638A (zh) * | 2012-05-29 | 2012-09-12 | 海南卫康制药(潜山)有限公司 | 注射用阿魏酸钠冻干粉组合物及其制备方法 |
CN108619522A (zh) * | 2017-03-15 | 2018-10-09 | 常州柚盾实业投资有限公司 | 一种含有酚酸的冻干赋形制剂及其制备方法 |
-
2010
- 2010-02-24 CN CN2010101130199A patent/CN101791302B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101791302A (zh) | 2010-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102391250A (zh) | 一种达比加群酯化合物、制备方法及其药物组合物 | |
WO2008100992A1 (en) | Intravenous solutions comprising ranolazine | |
CN108853032B (zh) | 一种注射用氟尿嘧啶组合物冻干粉剂 | |
CN101791302B (zh) | 含阿魏酸钠的药物组合物及其制备方法 | |
CN101585859A (zh) | 一种新的灯盏花乙素衍生物、其制备方法及其药物组合物 | |
CN101711746B (zh) | 一种注射用更昔洛韦冻干制剂及其制备方法 | |
CN101530392B (zh) | 一种奥美拉唑钠冻干脂质体制剂 | |
CN104257615A (zh) | 一种地佐辛冻干药物组合物及其制备方法 | |
WO2002013782A1 (en) | Oral delivery of peptide | |
WO2016045530A1 (zh) | 一种高复溶性及高稳定性的绿原酸冻干粉针 | |
EP3040067A1 (en) | Chlorogenic acid powder-injection and preparation method thereof | |
JP2021523195A (ja) | Hc−1119製剤及びその製造方法と使用 | |
CN102488650A (zh) | 一种环磷腺苷药物组合物及其制备方法 | |
CN102670956B (zh) | 一种中药组合物在制备抗心肌细胞凋亡和/或抗心肌细胞凋亡相关疾病的药物中的应用 | |
CN101455648A (zh) | 一种葛根素冻干制剂 | |
CN104211650A (zh) | 富马酸川芎嗪及其制备方法以及药物组合物 | |
CN104086531B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
KR101788658B1 (ko) | 신규 히드록시 홍화황색소 a의 의약용 정제염 | |
CN102512360A (zh) | 稳定安全的供注射用托拉塞米药物组合物 | |
CN104490802A (zh) | 红景天苷肠溶片及其制备方法 | |
CN105726495B (zh) | 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法 | |
US7427663B2 (en) | Cardio myopeptidin, the production and the use thereof | |
KR20150030725A (ko) | 계피유 및 그의 주성분 신남 알데히드로 제조된 항폐암 약물 및 그의 용도 | |
CN104434861B (zh) | 盐酸氨溴索渗透泵控释片及其制备方法 | |
CN103304424A (zh) | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100804 Assignee: Guangdong encyclopedia Pharmaceutical Co.,Ltd. Assignor: Wang Baoming Contract record no.: 2012110000120 Denomination of invention: Medicinal composition containing sodium ferulate and preparation method thereof Granted publication date: 20110921 License type: Common License Record date: 20120718 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160120 Address after: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee after: Beijing Bobangjiayuan Medical Technology Development Co.,Ltd. Address before: Room 12, building 93, Wanda Plaza, No. 100022 Jianguo Road, Beijing, Chaoyang District, China Patentee before: Wang Baoming |
|
TR01 | Transfer of patent right |
Effective date of registration: 20161222 Address after: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee after: XIZANG JIURUI HEALTH Co.,Ltd. Address before: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee before: Beijing Bobangjiayuan Medical Technology Development Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee after: JIURUI health Co.,Ltd. Address before: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee before: XIZANG JIURUI HEALTH Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110921 Termination date: 20210224 |